Gabapentin Approvals, Off-Label Use, and Lessons for Postmarketing Evaluation Efforts

JAMA. 2018 Feb 27;319(8):776-778. doi: 10.1001/jama.2017.21897.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Amines
  • Cyclohexanecarboxylic Acids*
  • Gabapentin
  • Humans
  • Off-Label Use*
  • Product Surveillance, Postmarketing
  • gamma-Aminobutyric Acid

Substances

  • Amines
  • Cyclohexanecarboxylic Acids
  • gamma-Aminobutyric Acid
  • Gabapentin